Clinical Trials Sponsored by BIOSANTECH

Total 87 results

BioSyntech Canada Inc.

Terminated

BST-DERMON Versus Standard of Care in the Treatment of Diabetic Foot Ulcers

Diabetic Foot Ulcer

Canada
BioNTech US Inc.

Recruiting

NEO-PTC-01 in Patients With Advanced or Metastatic Melanoma

Metastatic Melanoma | Unresectable Melanoma

Belgium, Netherlands, Spain
BioNTech RNA Pharmaceuticals GmbH

Completed

IVAC MUTANOME Phase I Clinical Trial

Melanoma

Austria, Germany
BioNTech Research & Development, Inc.

Recruiting

Study of HuMab-5B1 (MVT-5873) in Subjects With Pancreatic Cancer or Other Cancer Antigen 19-9 (CA19-9) Positive Malignancies

Pancreatic Cancer

United States
BioNTech RNA Pharmaceuticals GmbH

Completed

RBL001/RBL002 Phase I Clinical Trial (MERIT)

Melanoma

Austria, Germany
BioNTech SE

Recruiting

A Clinical Trial to Evaluate the Safety, Efficacy and Immune Responses After Vaccination With an Investigational RNA-based Vaccine Against Malaria

Malaria

United States
BioNTech SE

Recruiting

Safety and Immune Responses After Vaccination With Two Investigational RNA-based Vaccines Against Tuberculosis in BCG Vaccinated Volunteers

Tuberculosis

South Africa
BioNTech SE

Recruiting

Safety and Immune Responses After Vaccination With Two Investigational RNA-based Vaccines Against Tuberculosis in Healthy Volunteers

Tuberculosis

Germany
BioNTech SE

Recruiting

A Clinical Trial Investigating the Safety, Tolerability, and Therapeutic Effects of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Alone for Patients With a Form of Head and Neck Cancer Positive for Human Papilloma Virus 16 and Expressing the Protein PD-L1 (AHEAD-MERIT)

Recurrent Head and Neck Cancer | Unresectable Head and Neck Squamous Cell Carcinoma | Metastatic Head and Neck Cancer

Germany, United States, France, United Kingdom, Korea, Republic of, Spain, Poland, Belgium, Brazil, Taiwan, Italy, Canada, Czechia, Australia, Turkey, Mexico, Chile, Argentina, Austria, Hungary, Portugal, Sweden
BioNTech SE

Completed

A Trial Investigating the Safety and Effects of One BNT162 Vaccine Against COVID-19 in Healthy Adults

Covid-19 | Protection Against COVID-19

Germany
BioNTech SE

Completed

Safety and Immunogenicity of RNA-based Vaccines Against SARS-CoV-2 Variants in Healthy Participants

COVID-19 | SARS-CoV2 Infection | SARS-CoV-2 Acute Respiratory Disease | SARS (Disease)

United States, Germany, Turkey, South Africa
BioNTech SE

Terminated

Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT141 in Patients With Unresectable or Metastatic CLDN18.2-positive Gastric, Pancreatic, Ovarian and Biliary Tract Tumors

Gastric Cancer | Pancreatic Cancer | Solid Tumor | Metastatic Cancer | Cholangiocarcinoma | Esophageal Adenocarcinoma | Biliary Tract Cancer | Gastroesophageal Junction Adenocarcinoma

United States, Canada
BioNTech SE

Completed

Evaluation of the Safety and Tolerability of i.v. Administration of a Cancer Vaccine in Patients With Advanced Melanoma (Lipo-MERIT)

Melanoma

Germany
BioNTech SE

Active, not recruiting

A Trial Investigating the Safety and Effects of Four BNT162 Vaccines Against COVID-2019 in Healthy and Immunocompromised Adults

RNA Virus Infections | Virus Diseases | Vaccine Adverse Reaction | Infection Viral | Infections, Respiratory | Protection Against COVID-19 and Infections With SARS CoV 2

Germany
BioSante Pharmaceuticals

Completed

Safety and Efficacy of LibiGel® for Treatment of Hypoactive Sexual Desire Disorder in Postmenopausal Women (BLOOM)

Hypoactive Sexual Desire Disorder

United States, Canada
BioSante Pharmaceuticals

Completed

Efficacy and Safety of a Topical Estradiol Gel for Treatment of Postmenopausal Symptoms

Hot Flashes
BioNTech SE

Recruiting

A Clinical Trial in Healthy Volunteers to Study the Safety, Tolerability, and Immune Responses After Vaccination With an Investigational Vaccine Designed to Prevent Genital Herpes Lesions

Genital Herpes Simplex Type 2

United States
BioNTech SE

Recruiting

Safety and Preliminary Efficacy Trial of BNT142 in Patients With CLDN6-positive Solid Tumors

Solid Tumor

United States, Spain, Singapore, United Kingdom
BioNTech SE

Recruiting

Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer (LuCa-MERIT-1)

Non-Small Cell Lung Cancer

Spain, Germany, Turkey, United States, Hungary, United Kingdom, Poland
BioNTech SE

Recruiting

Dose Escalation Trial of BNT152+153 in Patients With Cancer

Solid Tumor

United States, Czechia
BioNTech SE

Active, not recruiting

Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT411

Solid Tumor | Extensive-stage Small Cell Lung Cancer

United States, Spain, United Kingdom, Germany
BioNTech SE

Active, not recruiting

Safety and Immune Responses After Vaccination With an Investigational RNA-based Vaccine Against Malaria

Malaria

United States
BioNTech SE

Terminated

PRO-MERIT (Prostate Cancer Messenger RNA Immunotherapy) (PRO-MERIT)

Prostate Cancer

United States, Germany, United Kingdom, Hungary
BioNTech SE

Completed

A Trial Investigating the Safety and Effects of One or Two Additional Doses of Comirnaty or One Dose of BNT162b2s01 in BNT162-01 or BNT162-04 Trial Subjects

COVID-19 | SARS-CoV-2 Infection

Germany
BioSante Pharmaceuticals

Completed

Safety and Efficacy of LibiGel® for Treatment of Hypoactive Sexual Desire Disorder in Surgically Menopausal Women (BLOOM)

Hypoactive Sexual Desire Disorder

United States, Canada
BIOSANTECH
Assistance Publique Hopitaux De Marseille

Unknown

Evaluation on Seropositive Patients of a Synthetic Vaccine Targeting the HIV Tat Protein (EVATAT)

AIDS

France
BioNTech Cell & Gene Therapies GmbH

Recruiting

A Clinical Study of the Safety and Effectiveness of an Investigational Cell Therapy Given With and Without an Investigational RNA-based Vaccine in Patients With Organ Tumors

Solid Tumor

Australia, Germany, Netherlands, Sweden
BioNTech US Inc.
Apexigen, Inc.

Terminated

A Personal Cancer Vaccine (NEO-PV-01) and APX005M or Ipilimumab With Nivolumab in Patients With Advanced Melanoma

Metastatic Melanoma

United States
BioNTech Research & Development, Inc.

Terminated

Study of 177Lu Human Monoclonal Antibody 5B1 (MVT-1075) in Combination With a Blocking Dose of MVT-5873 as Radioimmunotherapy

Pancreatic Carcinoma | Tumors That Express CA 19-9

United States
BioNTech SE

Recruiting

Safety, Tolerability, and Efficacy of mFOLFIRINOX ± BNT321 as Adjuvant Therapy Following Curative Resection in Patients With Pancreatic Adenocarcinoma

Pancreatic Cancer

United States
BioNTech SE

Recruiting

A Clinical Study Investigating the Safety and Immune Responses After Immunization With Investigational Monkeypox Vaccines

Monkeypox

United Kingdom, United States
BioNTech SE

Recruiting

Epidemiological Study to Monitor Study Participants With Resected Stage II (High Risk) or Stage III Colorectal Cancer for Circulating Tumor DNA Before, During and After Their Treatment With Adjuvant Chemotherapy

Colorectal Cancer Stage II | Colorectal Cancer Stage III

United States, Spain, Germany, Belgium
BioNTech SE

Active, not recruiting

BNT151 as a Monotherapy and in Combination With Other Anti-cancer Agents in Patients With Solid Tumors

Solid Tumor

United States, Spain
BioSante Pharmaceuticals

Completed

Extension Study to Assess Persistence of Benefit of LibiGel for the Treatment of Hypoactive Sexual Desire Disorder (HSDD)

Hypoactive Sexual Desire Disorder

United States, Canada
BioSante Pharmaceuticals

Completed

Safety and Efficacy of LibiGel® for the Treatment of Hypoactive Sexual Desire Disorder in Surgically Menopausal Women (BLOOM)

Hypoactive Sexual Desire Disorder

United States, Canada
BioNTech US Inc.
Bristol-Myers Squibb

Completed

A Personal Cancer Vaccine (NEO-PV-01) w/ Nivolumab for Patients With Melanoma, Lung Cancer or Bladder Cancer

Melanoma | Carcinoma, Non-Small-Cell Lung | Lung Cancer | Urinary Bladder Cancer | Skin Cancer | Transitional Cell Carcinoma of the Bladder | Malignant Melanoma | Bladder Tumors

United States
BioNTech Research & Development, Inc.
SciQuus Oncology

Terminated

Phase 1 Imaging Study of 89Zr-DFO-HuMab-5B1 With HuMab-5B1

Pancreatic Carcinoma | Tumors That Express CA19-9

United States
BioNTech SE
Genmab

Recruiting

Safety and Preliminary Efficacy of BNT314 With or Without an Immune Checkpoint Inhibitor in Cancer Patients With Malignant Solid Tumors

Advanced Malignant Solid Tumor

United States, United Kingdom
Genmab
BioNTech SE

Not yet recruiting

GEN1046 in Combination With Anticancer Agents for the Treatment of Advanced Endometrial Cancer

Advanced Endometrial Cancer

Korea, Republic of, Spain, Belgium, United States, Denmark, Italy
Genmab
BioNTech SE

Active, not recruiting

GEN1046 Safety Trial in Patients With Malignant Solid Tumors

Cervical Cancer | Squamous Cell Carcinoma of the Head and Neck | Triple Negative Breast Cancer | Non-small Cell Lung Cancer | Solid Tumors | Endometrial Carcinoma | Urothelial Carcinoma

United States, Spain, Israel, Czechia, Georgia, Italy, Poland, Turkey, Hungary, Ukraine
BioNTech SE
Pfizer

Withdrawn

A Study to Learn About Bivalent COVID-19 RNA Vaccine Candidate(s) in Healthy Infants and Children

COVID-19
BioNTech SE
Pfizer

Active, not recruiting

A Study to Learn About New COVD-19 RNA Vaccine Candidates for New Variants in Healthy Individuals

COVID-19 | SARS-CoV-2 Infection

United States
BioNTech SE
Pfizer

Completed

Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals

COVID-19 | SARS-CoV-2 Infection

United States, Germany, Turkey, South Africa, Argentina, Brazil
BioNTech SE
Pfizer

Recruiting

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Combined Modified RNA Vaccine Candidate Against COVID-19 and Influenza.

COVID-19 | Influenza

United States
BioNTech SE
Pfizer

Active, not recruiting

Safety and Effects of an Investigational COVID-19 Vaccine as Booster in Healthy People

COVID-19 | SARS-CoV-2 Infection

United States
BioNTech SE
Pfizer

Completed

A Phase 1/2/3 Study to Evaluate the Safety, Tolerability, and Immunogenicity of an RNA Vaccine Candidate Against COVID-19 in Healthy Children

SARS-CoV-2 Infection, COVID-19

United States, Spain, Finland, Poland, Mexico, Brazil
BioNTech SE
Pfizer

Completed

To Evaluate the Safety, Tolerability, and Immunogenicity of BNT162b2 Against COVID-19 in Healthy Pregnant Women 18 Years of Age and Older

COVID-19 | SARS-CoV-2 Infection | Maternal Immunization

United States, United Kingdom, Spain, Brazil, South Africa
BioNTech SE
Pfizer

Completed

To Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of BNT162b2 Boosting Strategies Against COVID-19 in Participants ≥12 Years of Age.

COVID-19 | SARS-CoV-2 Infection

United States, Brazil, South Africa, Germany, Canada, Israel
BioNTech SE
Pfizer

Completed

Study to Evaluate the Safety, Tolerability, and Immunogenicity of an RNA Vaccine Candidate Against COVID-19 in Healthy Japanese Adults

COVID-19 | SARS-CoV-2 Infection

Japan
BioNTech SE
Pfizer

Completed

A Study to Evaluate Safety, Tolerability, & Immunogenicity of Multiple Formulations of BNT162b2 Against COVID-19 in Healthy Adults

COVID-19 | SARS-CoV-2 Infection

United States

3

Subscribe